All times are listed in CEST (Central European Summer Time)

Displaying One Session

View
South Hall 2 Wed, 30.03.2022 18:15 - 19:45

Takeda - Novel therapies for EGFR exon 20 insertions and ALK-positive NSCLC: Developments and implications (ID 35)

Time
18:15 - 19:45
Location
South Hall 2
Date
Wed, 30.03.2022
Takeda - Novel therapies for EGFR exon 20 insertions and ALK-positive NSCLC: Developments and implications Industry Satellite Symposium

Welcome and introduction (ID 284)

Lecture Time
18:15 - 18:20
Speakers
  • Martin Reck, Grosshansdorf, DE
Session Name
Takeda - Novel therapies for EGFR exon 20 insertions and ALK-positive NSCLC: Developments and implications
Location
South Hall 2, Prague Congress Centre, Prag, Czech Republic
Date
Wed, 30.03.2022
Time
18:15 - 19:45
Takeda - Novel therapies for EGFR exon 20 insertions and ALK-positive NSCLC: Developments and implications Industry Satellite Symposium

Precision medicine in NSCLC: From biomarker testing to therapy selection (ID 285)

Lecture Time
18:20 - 18:35
Speakers
  • Martin Reck, Grosshansdorf, DE
Session Name
Takeda - Novel therapies for EGFR exon 20 insertions and ALK-positive NSCLC: Developments and implications
Location
South Hall 2, Prague Congress Centre, Prag, Czech Republic
Date
Wed, 30.03.2022
Time
18:15 - 19:45
Takeda - Novel therapies for EGFR exon 20 insertions and ALK-positive NSCLC: Developments and implications Industry Satellite Symposium

Emerging therapies for advanced NSCLC With EGFR Exon 20 insertion mutations: Developments and implications (ID 286)

Lecture Time
18:35 - 19:00
Speakers
  • Maurice Pérol, Lyon, FR
Session Name
Takeda - Novel therapies for EGFR exon 20 insertions and ALK-positive NSCLC: Developments and implications
Location
South Hall 2, Prague Congress Centre, Prag, Czech Republic
Date
Wed, 30.03.2022
Time
18:15 - 19:45
Takeda - Novel therapies for EGFR exon 20 insertions and ALK-positive NSCLC: Developments and implications Industry Satellite Symposium

Frontline treatment of ALK-Positive NSCLC: Therapy considerations and selection (ID 287)

Lecture Time
19:00 - 19:25
Speakers
  • Sanjay Popat, London, GB
Session Name
Takeda - Novel therapies for EGFR exon 20 insertions and ALK-positive NSCLC: Developments and implications
Location
South Hall 2, Prague Congress Centre, Prag, Czech Republic
Date
Wed, 30.03.2022
Time
18:15 - 19:45
Takeda - Novel therapies for EGFR exon 20 insertions and ALK-positive NSCLC: Developments and implications Industry Satellite Symposium

Live Q&A / discussion (ID 288)

Lecture Time
19:25 - 19:43
Session Name
Takeda - Novel therapies for EGFR exon 20 insertions and ALK-positive NSCLC: Developments and implications
Location
South Hall 2, Prague Congress Centre, Prag, Czech Republic
Date
Wed, 30.03.2022
Time
18:15 - 19:45
Takeda - Novel therapies for EGFR exon 20 insertions and ALK-positive NSCLC: Developments and implications Industry Satellite Symposium

Concluding remarks (ID 289)

Lecture Time
19:43 - 19:45
Speakers
  • Martin Reck, Grosshansdorf, DE
Session Name
Takeda - Novel therapies for EGFR exon 20 insertions and ALK-positive NSCLC: Developments and implications
Location
South Hall 2, Prague Congress Centre, Prag, Czech Republic
Date
Wed, 30.03.2022
Time
18:15 - 19:45